Cc-486 Improves Overall Survival (Os) And Relapse-Free Survival (Rfs) For Patients With Acute Myeloid Leukemia (Aml) In First Remission After Intensive Chemotherapy (Ic), Regardless Of Amount Of Consolidation Received: Results From The Phase Iii Quazar Aml-001 Maintenance Trial

Background: Approximately 40-60% of older patients (pts) with AML achieve complete remission (CR) with IC. Factors influencing the use of consolidation after induction include disease-related considerations, extent of hematopoietic recovery, pt fitness, and physician and pt preference. Most older pts who achieve AML remission will experience disease relapse despite consolidation therapy (Schlenk, Haematologica, 2018). In the phase III, randomized, double-blind QUAZAR AML-001 Maintenance Trial, CC-486, an oral hypomethylating agent, was shown to significantly prolong OS and RFS vs. placebo (PBO) in pts with AML in first remission following induction ± consolidation. Prior to study entry, the use of consolidation chemotherapy and number of consolidation cycles was at the discretion of the treating physician, with study eligibility not contingent on the use of consolidation.